Plus Therapeutics Inc - PSTV STOCK NEWS

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced its Q1 2023 financial results and key milestones including the completion of Part A of the ReSPECT-LM trial. Cash balance decreased to $12.7 million from $18.1 million at year-end 2022. The company recorded $506,000 in grant revenue and total operating expenses rose to $5.2 million, attributed mainly to a $750,000 license payment. The net loss for the quarter was $4.8 million or $(0.14) per share. Looking ahead, the company aims to publish ReSPECT-GBM Phase 1 data and expand enrollment in ongoing trials, with a focus on capital efficiency through potential grant funding.

Plus Therapeutics (PSTV) has completed enrollment for Cohort 8 in the ReSPECT-GBM Phase 1/2a clinical trial, focusing on rhenium (186Re) obisbemeda for treating recurrent glioblastoma (GBM). A total of 27 patients have been treated in the dose escalation phase. In this latest cohort, patients with large tumors received a dose of 41.5 mCi in 16.34 mL. Plus is also advancing a Phase 2b trial for patients with small- to medium-sized tumors, offering retreatment options for some. The absorbed dose achieved was up to 740 Gray, indicating strong targeting capabilities. The FDA has granted Orphan Drug and Fast Track designations for the treatment. Additional safety and efficacy data will be shared with FDA and at future medical meetings.

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for central nervous system cancers, announced that Dr. Norman LaFrance will present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. The panel will discuss 'Emerging Approaches to Radiotherapy: Plus Therapeutics & Y-mAbs Therapeutics.' Plus Therapeutics specializes in developing treatments for challenging conditions like recurrent glioblastoma and leptomeningeal metastases through innovative techniques combining image-guided local beta radiation and targeted drug delivery. The company has established a solid supply chain via strategic partnerships, ensuring the advancement and potential commercialization of its therapies.

Plus Therapeutics (PSTV) has advanced its clinical trial for rhenium (186Re) obisbemeda, targeting leptomeningeal metastases (LM), by completing Cohort 3 of the Phase 1/2a trial. The company expanded its clinical trial sites, adding Northwestern Memorial Hospital, which facilitates broader patient access. Notably, no dose-limiting toxicities were observed, indicating a promising safety profile. The FDA has already granted Fast Track designation for the treatment, highlighting its potential. The company expects to share complete Phase 1/Part A data by the second half of 2023, with a further meeting with the FDA planned to discuss next steps for Part B.

Plus Therapeutics, Inc. (PSTV) will announce its Q1 2023 financial results on April 20, 2023, after market close. Following this, the management team will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Plus Therapeutics specializes in developing targeted radiotherapeutics for challenging cancers, utilizing a proprietary nanotechnology platform for enhanced drug delivery through liposomal encapsulation. More details about the event can be found on their investor relations website, along with a replay available for 90 days post-call.

Plus Therapeutics (PSTV) has successfully treated the first patient in Cohort 8 of its ReSPECT-GBM Phase 1/2a trial for rhenium (186Re) obisbemeda in recurrent glioblastoma. The trial has treated 25 patients without dose-limiting toxicities. Cohort 8 is now enrolling with a dose of 41.5 mCi, allowing treatment of larger tumors. The Phase 2 trial has treated five patients with a lower dose of 22.3 mCi. So far, safety and efficacy signals from the trials are promising, with no treatment-emergent toxicities noted. The FDA has granted Orphan Drug and Fast Track designations for this investigational therapy.

Plus Therapeutics (PSTV) has successfully initiated treatment of the first patient in Cohort 3 of its ReSPECT-LM Phase 1/2a clinical trial, aimed at treating leptomeningeal metastases from solid tumors. This follows the completion of previous cohorts without observing dose-limiting toxicities, with doses administered up to 26.4 millicuries. Encouraging safety and response data have been reported, showing significant reductions in cerebrospinal fluid tumor cell counts. The FDA has granted Fast Track designation for the therapy, supported by a $17.6 million grant from CPRIT. Preliminary results are expected to be presented in the latter half of 2023.